Literature DB >> 25545217

Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.

Andreas Wicki1, Dominik Witzigmann2, Vimalkumar Balasubramanian3, Jörg Huwyler4.   

Abstract

Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer nanomedicine; Clinical trials; Drug delivery; Liposome; Nanoparticle; Targeting

Mesh:

Year:  2014        PMID: 25545217     DOI: 10.1016/j.jconrel.2014.12.030

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  288 in total

Review 1.  Polymeric Nanostructures for Imaging and Therapy.

Authors:  Mahmoud Elsabahy; Gyu Seong Heo; Soon-Mi Lim; Guorong Sun; Karen L Wooley
Journal:  Chem Rev       Date:  2015-08-04       Impact factor: 60.622

Review 2.  Nanotechnologies for biomedical science and translational medicine.

Authors:  James R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

Review 3.  Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.

Authors:  Sophie Marchal; Amélie El Hor; Marie Millard; Véronique Gillon; Lina Bezdetnaya
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

4.  Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.

Authors:  Jiang-Jiang Qin; Wei Wang; Sushanta Sarkar; Ruiwen Zhang
Journal:  J Control Release       Date:  2016-07-06       Impact factor: 9.776

5.  Contribution of Kupffer cells to liposome accumulation in the liver.

Authors:  Emma Samuelsson; Haifa Shen; Elvin Blanco; Mauro Ferrari; Joy Wolfram
Journal:  Colloids Surf B Biointerfaces       Date:  2017-07-15       Impact factor: 5.268

6.  Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma.

Authors:  Forrest M Kievit; Kui Wang; Tatsuya Ozawa; Aria W Tarudji; John R Silber; Eric C Holland; Richard G Ellenbogen; Miqin Zhang
Journal:  Nanomedicine       Date:  2017-06-11       Impact factor: 5.307

Review 7.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

Review 8.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

9.  Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor.

Authors:  Nenad L Ignjatović; Katarina M Penov-Gaši; Victoria M Wu; Jovana J Ajduković; Vesna V Kojić; Dana Vasiljević-Radović; Maja Kuzmanović; Vuk Uskoković; Dragan P Uskoković
Journal:  Colloids Surf B Biointerfaces       Date:  2016-09-28       Impact factor: 5.268

10.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.